Clinical Trial Update: Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating ABI-007, a nanoparticle paclitaxel formulation, for prevention of in-stent restenosis in coronary arteries; the study is completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Restenosis

Drugs mentioned

• ABI-007 (nanoparticle paclitaxel) (paclitaxel nanoparticle formulation)

Snippet

Sponsor: Celgene Corporation | Conditions: Coronary Restenosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2012-03-08